Effects of Jinlong Capsule on expressions of interleukin-2 and soluble interleukin-2 receptor in patients with primary liver cancer after transarterial chemoembolization therapy
Author:
- 15 September 2008
- journal article
- abstracts
- Published by Journal of Chinese Integrative Medicine Press in Journal of Chinese Integrative Medicine
- Vol. 6 (9) , 907-910
Abstract
To observe and discuss the dynamic changes of interleukin-2 (IL-2) and soluble interleukin-2 receptor (sIL-2R) and their significance in the patients with primary liver cancer after transarterial chemoembolization (TACE) therapy combined with Jinglong Capsule. A total of 48 patients with primary liver cancer, who failed to be treated by major surgery, were randomly divided into two groups: Jinlong Capsule group (TACE therapy plus Jinlong Capsule) and control group (TACE therapy alone). There were 24 cases in each group. The levels of peripheral blood IL-2 and slL-2R were measured before the first TACE and 1, 7 and 15 days after the second TACE respectively by using double-antibody sandwich enzyme-linked immunosorbent assay. The data from Jinlong Capsule group were compared with those from the control group. The level of sIL-2R in Jinlong Capsule group was significantly lower than that in the control group (P<0.05), while the level of IL-2 was significantly higher than that in the control group (P<0.05). Jinlong Capsule can significantly improve the lymphocyte function of the patients with primary liver cancer after TACE. The levels of IL-2 and sIL-2R can be considered as the valuable parameters for evaluating the effects on primary liver cancer, and Jinlong Capsule is helpful for the patients with primary liver cancer.Keywords
This publication has 7 references indexed in Scilit:
- Natural killer cells actively patrol peripheral lymph nodes forming stable conjugates to eliminate MHC-mismatched targetsProceedings of the National Academy of Sciences, 2007
- Effects of Interleukin-2 Treatment on CD1d-Restricted Natural Killer T CellsClinical Cancer Research, 2007
- Immunotherapy for neuroblastoma using syngeneic fibroblasts transfected with IL-2 and IL-12British Journal of Cancer, 2007
- Cytokine-Based Immunotherapy for Advanced Kidney Cancer: Past Results and Future Perspectives in the Era of Molecularly Targeted AgentsThe Scientific World Journal, 2007
- Soluble interleukin-2 receptor in stage I–III melanomaCytokine, 2006
- Difference in cytotoxicity against hepatocellular carcinoma between liver and periphery natural killer cells in humansHepatology, 2006
- Soluble Interleukin-2 Receptor Levels in Hepatocellular Cancer: a More Sensitive Marker Than Alfa FetoproteinAnnals of Surgical Oncology, 1999